Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Editorial Volume 7 Issue 3

Precision Therapy in Oncology

Mallik Singaraju*

Radiation Oncology, Continental Hospital, India

*Corresponding Author: Mallik Singaraju, Radiation Oncology, Continental Hospital, India.

Received: February 20, 2023; Published: April 01, 2023

Cancer is second most common cause of death in the world. As the technology is advancing, the number of newly diagnosed cancer cases are on raise. Especially, in advanced stage. A decade back, the treatment for advanced cancers was primarily by chemotherapeutic agents. But now, targeted therapies are becoming increasingly popular.

References

Citation

Citation: Mallik Singaraju. “Mutational Screening and Prenatal Diagnosis of β-thalassemia in Pakistani Families" Acta Scientific Cancer Biology 7.3 (2023): 01-02.

Copyright

Copyright: © 2023 Mallik Singaraju. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US